Amsterdam, The Netherlands, June 13, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces that it has raised €5 million in gross proceeds through a private placement (the “Transaction”) of new shares (the “New Shares”) completed prior to the open of the market today.
The Company has placed 746,269 New Shares with a small group of existing and new institutional investors at a price of €6.70 per New Share, which represents a 11% discount to the closing price of June 12, 2017. The New Shares represent 5.3% of the current number of outstanding shares (pre-Transaction) and will bring the total number of shares (post-Transaction) to 14,712,770. In addition, the investors have received 746,269 5-year warrants entitling them to subscribe for 746,269 new Company shares at a warrant exercise price of €7.70 (the exercise price being subject to adjustment in case of certain corporate and dilutive events).
The New Shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels following their issuance, which is expected to take place on June 15, 2017.
Kiadis Pharma will use the net proceeds of the Transaction to advance the clinical development of the Company’s ATIR products and for general corporate purposes.
Arthur Lahr, Chief Executive Officer of Kiadis Pharma, commented: “Having recently filed a Marketing Authorization Application for ATIR101TM with EMA, the Company continues to make good progress regarding the Phase III trial and preparing for EU commercialization. We executed this private fundraising to quickly augment our cash position while we work on broader funding initiatives. In this Transaction, we are pleased to see existing shareholders increasing their holdings, and welcome new specialist healthcare investors.
Chardan acted as Sole Bookrunner and Placement Agent for the Transaction. Saola Healthcare Partners acted as financial advisor to Kiadis Pharma.

Leave a comment

Your email address will not be published. Required fields are marked *